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KAJIAN KAWALAN KES BERSARANG KE ATAS FAKTOR PENENTU 
TUBERKULOSIS BERULANG, KOMPLIANS DAN PENILAIAN KOS DI 
KAWASAN BANDAR YEMEN 
 
ABSTRAK 
Tuberkulosis (TB) dianggap sebagai salah satu masalah kesihatan masyarakat yang 
paling utama di Yemen. Ia berada di tangga ke empat dalam senarai masalah utama 
kesihatan masyarakat.  Penyakit TB berulang dan pesakit yang tidak komplians 
merupakan masalah yang serius yang membawa kepada pelbagai komplikasi. Kajian 
ini bertujuan untuk mengkaji pengaruh pelbagai jenis faktor ke atas penyakit TB 
berulang dan komplians pesakit serta menganggarkan bebanan dari segi ekonomi 
yang disebabkan oleh masalah ini. Kajian ini menggunakan reka bentuk kajian 
kawalan kes bersarang secara prospektif dan melibatkan seramai 814 pesakit TB 
pulmonari positif baru berdaftar bagi tempoh satu tahun (01-07-2007/31-06-2008) 
dalam 10 kawasan pentadbiran di Yemen.  Pengumpulan data termasuk dua fasa 
utama: menemuramah pesakit yang terlibat pada tempoh akhir fasa intensif dan 
mengkaji semula kad perubatan dan pendaftaran TB mereka di akhir tempoh rawatan.  
Faktor-faktor yang diselidiki berkaitan masalah TB berulang adalah  demografi, 
sosioekonomi, faktor berkaitan rawatan dan penyakit, dan juga faktor-faktor yang 
dinilai 2-3 bulan selepas rawatan, serta komplians terhadap terapi dengan ubat anti-
TB. Manakala faktor yang dikaji ke atas masalah komplians adalah demografi dan 
sosioekonomi termasuk pengetahuan pesakit berkaitan penyakit TB, pendidikan 
kesihatan di pusat kesihatan dan kesan mudarat ubat anti-TB.  Kajian ini juga menilai 
kos langsung daripada perspektif kerajaan. Ujian Student T dan Mann-Whitney U 
telah digunakan pada nilai alfa 0.05. Kaedah regresi logistik multivariat digunakan 
untuk menentukan faktor-faktor berkaitan kes TB berulang dan pesakit yang tidak 
xvii 
 
komplians. Analisis deskriptif menunjukkan 90% daripada responden dalam 
linkungan umur yang produktif (15-54 tahun).  Terdapat 44 kes berulang dan 133 kes 
tidak komplians dalam kalangan sampel pesakit yang disusuli.  Analisis regresi 
logistik multivariat  menunjukkan status pekerjaan (OR 3.93, 95% CI 1.41, 10.99), 
bilangan batang rokok yang dihisap sehari (OR 11.76, 95% CI 1.55, 89.11), 
kehadiran rongga (cavitations) (OR 4.67, 95% CI 1.86, 11.70), kehilangan berat 
badan (OR 8.11, 95% CI 3.10, 21.39), kepatuhan pengambilan ubat dalam fasa 
rawatan TB berterusan (OR 17.94, 95% CI 1.69, 190.64), diabetes (OR 14.67, 95% 
CI 3.57, 60.20) dan komplians (OR 3.73, 95% CI 1.39, 9.99) merupakan faktor yang 
berkait secara signifikan dengan TB berulang. Manakala tahap literasi (OR 1.87, 
95% CI 1.08,3.25), status pekerjaan (OR 2.19, 95% CI 1.26,3.80), masa perjalanan 
(OR 1.03, 95% CI 1.01,1.04), masa menunggu (OR 1.05, 95% CI 1.03,1.06), status 
tempat tinggal (OR 6.72, 95% CI 1.99,22.63), sokongan keluarga (OR 4.05, 95% CI 
1.17,14.04), stigma (OR 1.75, 95% CI 1.06,2.89),  tabiat mengunyah Qat (OR 3.26, 
95% CI 1.89,5.60) dan pengetahuan pesakit tentang TB (OR 0.84, 95% CI 0.70,0.99) 
merupakan faktor risiko bagi masalah tidak komplians. Tempat tinggal juga 
merupakan faktor risiko bagi masalah tidak komplians dengan julat OR di antara 
7.45, 95% CI 1.77, 31.42 (kawasan Metropolitan) dan 42.13, 95% CI 8.02, 221.37 
(kawasan Hajjah) dalam kalangan kawasan pentadbiran. Dari segi kos perubatan 
langsung, terdapat perbezaan yang signifikan (p < 0.001) dalam kos median antara 
kumpulan berulang (M=93.00, IQR=91.86-93.42) dan tidak berulang (M=35.25, 
IQR=34.95-35.25). Kos yang ditanggung oleh kerajaan untuk merawat satu kes 
berulang dan tidak berulang adalah masing-masing US$92.31 dan U$$35.02. Kos 
tambahan yang ditanggung oleh kerajaan untuk merawat satu kes berulang adalah 
US$57.29.  Walau bagaimanapun, dalam kalangan komponen perkhidmatan 
xviii 
 
kesihatan, perbelanjaan ubat menunjukkan kos yang tertinggi untuk pesakit tidak 
berulang dan berulang, masing-masing 59.0% dan 67.6%.  Sebagai kesimpulan, 
dapatan kajian ini menunjukkan kadar tahap berulang (5.7%) dan tidak komplians 
(16.3%) adalah tinggi dalam kalangan pesakit TB. Terdapat ramai pesakit yang 
mempunyai pengetahuan yang terhad tentang penyebaran dan rawatan penyakit TB.  
Intervensi untuk mengurangkan masalah berulang dan kadar tidak komplians harus 
dilaksanakan. Kajian ini menyarankan penggunaan satu rawatan standard yang 
mengandungi rifampisin dalam fasa berterusan bagi rawatan TB berongga.  Kajian 
ini turut menyarankan  strategi untuk memperbaiki status sosioekonomi rakyat dan 
mencari rawatan TB yang berkesan kos.     
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A NESTED CASE-CONTROL STUDY ON PREDICTORS OF 
TUBERCULOSIS RELAPSE, COMPLIANCE AND COST EVALUATION IN 
URBAN AREAS OF YEMEN 
 
ABSTRACT 
Tuberculosis (TB) is considered to be one of the major public health problems in 
Yemen. It is estimated that TB is the fourth cause of death based on hospitals 
statistics. Relapse of TB and patients’ non-compliance are serious problems leading 
to several complications. The present study was aimed to examine the influence of 
different factors on relapse of TB and patients’ compliance as well as to estimate the 
economic burden as consequences of relapse. The study design was a nested case 
control study that included 814 new smear positive pulmonary TB patients registered 
during a one year period (01-07-2007/31-06-2008) in ten governorates of Yemen. 
Data collection included two main phases; interviewing the participants at the end of 
intensive phase and reviewing their medical cards and TB registers at the end of the 
treatment. Factors investigated on relapse were demographic, socioeconomic, 
treatment and disease-related factors as well as factors evaluated after 2-3 months of 
treatment, and compliance with anti-TB therapy, while the factors investigated on 
compliance were demographic and socioeconomic factors as well as patients’ 
knowledge on TB, health education at health centre and adverse reactions of anti-TB 
drugs. A direct cost of relapse from government perspective was also evaluated. 
Student T-test and Mann-Whitney U test were used at alpha level of 0.05. Multiple 
logistic regression was employed to determine independently associated factors with 
relapse and patients’ non-compliance. The descriptive analysis in this study showed 
that 90% of respondents were at their most economically productive age (15-54 years 
old). Forty four relapse and 133 non-compliant cases were identified during the 
xx 
 
follow-up period. Multiple logistic regression analysis showed that the employment 
status (OR 3.93, 95% CI 1.41, 10.99), number of cigarettes smoked per day (OR 
11.76, 95% CI 1.55, 89.11), presence of cavitations (OR 4.67, 95% CI 1.86, 11.70), 
weight loss (OR 8.11, 95% CI 3.10, 21.39), adherence in continuous phase (OR 
17.94, 95% CI 1.69, 190.64), diabetes (OR 14.67, 95% CI 3.57, 60.20) and 
compliance (OR 3.73, 95% CI 1.39, 9.99) were significantly associated with TB 
relapse. While literacy (OR 1.87, 95% CI 1.08,3.25), employment status (OR 2.19, 
95% CI 1.26,3.80), travelling time (OR 1.03, 95% CI 1.01,1.04), waiting time (OR 
1.05, 95% CI 1.03,1.06), living status (OR 6.72, 95% CI 1.99,22.63), family support 
(OR 4.05, 95% CI 1.17,14.04), stigma (OR 1.75, 95% CI 1.06,2.89), Qat-chewing 
habit (OR 3.26, 95% CI 1.89,5.60) and patients’ knowledge on TB (OR 0.84, 95% CI 
0.70,0.99) were risk factors for non-compliance. The place of residence was also 
found to be a risk factor for non-compliance with a range of OR between 7.45, 95% 
CI 1.77, 31.42 (Metropolitan) and 42.13, 95% CI 8.02, 221.37 (Hajjah) among the 
governorates. In terms of direct medical cost, there was a significant difference in 
median cost between relapse (M=93.00, IQR=91.86-93.42) and non-relapse 
(M=35.25, IQR=34.95-35.25) groups; p < 0.001. The costs incurred by government 
to treat one relapse and non-relapse case were US$92.31 and U$$35.02, respectively. 
The extra cost incurred by government to treat one relapse case was US$57.29. 
However, the drug expenditures among health service components represented the 
highest cost for non-relapse and relapse patients (59.0% and 67.6%, respectively). In 
conclusion, the study findings showed high relapse (5.7%) and non-compliance 
(16.3%) rates among TB patients. A large proportion of patients had limited 
knowledge about the transmission and treatment of TB. Interventions to reduce 
relapse and non-compliance rates should be instituted. This study suggests using a 
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standard treatment regimen that contains rifampicin in the continuous phase for 
treatment cavitary TB. Strategies to improve socioeconomic status of the general 
population are recommended. It is also recommended that the cost effectiveness of 
TB treatment should be explored.   
 
 1 
CHAPTER 1 
INTRODUCTION 
 
This chapter will provide an overview of tuberculosis in terms of 
pathogenesis and transmission, diagnosis, treatment and the current global strategy 
for control of the disease. Thereafter, a situation of tuberculosis, history development 
and organization, and organizational framework of National Tuberculosis Control 
Programme (NTCP) in Yemen will be explored.  Then, an overview on relapse of 
tuberculosis as a problem in Yemen will be presented, followed by exploring the 
general themes of the economic impact of tuberculosis, research problem statement 
and rational of the study. Finally, the chapter will present the study aims and 
significance of the study. 
 
1.1 Overview on Tuberculosis 
1.1.1 Definition and Global Situation 
Tuberculosis (TB) is a contagious disease caused by an organism called 
Mycobacterium tuberculosis. These organisms are also known as tubercle bacilli. 
Strikingly, about one third of the world’s population is infected with M. tuberculosis 
and at risk of developing the disease. In the meantime, more than eight million 
people develop active tuberculosis every year. In 2009, 9.4 million cases of 
tuberculosis were reported globally which is equivalent to 137 cases per 100000 
population.  The mortality of this disease is high as two million people every year 
worldwide. Among all of tuberculosis mortality cases reported globally, 98% of the 
death incidences are reported from developing countries which represented 25% of 
all avoidable deaths. About 95% of global TB cases occurred in developing 
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countries, 75% of cases are in the most economically productive age group (15-54 
years old). (World Health Organization [WHO], 2003a; WHO, 2003; WHO, 2010).  
Although TB has the potential to cause the infection in various parts of the 
human body, it usually affects the lungs. The person can have TB infection itself 
which does not cause any symptom (TB disease) because the germs that cause TB 
disease can remain dormant or latent in the host’s body for several years. People with 
TB infection whose immune system is weakened are more likely to develop a clinical 
TB disease. 5-10% of the people who have the TB infection may develop the disease 
at certain time of their lives. In the same context, leaving the individual who has the 
TB disease without treatment will infect an average of 10-15 people with TB every 
year. Without treatment, 50% of patients with pulmonary tuberculosis (PTB) will die 
within 5 years. However, 25% of patients will remain sick with chronic, infectious 
TB. Meanwhile, the other 25% will be spontaneously recovered and be healthy (due 
to strong immune defenses) but they could be sick again at any time. Remarkably, 
the co-infection diseases such as human immunodeficiency virus (HIV) will 
significantly increase the risk of developing TB. For instance, 50% of the people 
infected with both HIV, and M. tuberculosis will become sick of TB during their 
lifetime (Corbett et al., 2003; WHO, 2003a; WHO, 2004).  
 
1.1.2 Tuberculosis Pathogenesis and Transmission 
The most important source of infection is a person with smear positive PTB. 
Untreated active smear positive PTB case will infect an average of 10-15 people per 
year (WHO, 2003a). The tubercle bacilli can not survive when they are exposed to 
the direct sunlight for more than 5 minutes, but they can survive in the dark for long 
periods (WHO, 2004). It implies that the transmission of TB usually occurs indoors. 
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The extent of exposure to the droplet nuclei (duration and dose) and the susceptibility 
of the host determine an individual’s risk of infection (Rieder, 1999).  
Primary infection occurs when a person is newly exposed to tubercle bacilli. 
Droplet nuclei are tiny enough to escape the mucocilliary defense of the bronchi, 
lodge in the terminal alveoli of the lungs and begin to multiply forming a lesion 
called Ghon focus. The Ghon focus and related hilar lymphadenopathy form a 
primary complex. Usually the immune response controls multiplying bacilli, 
resulting in a latent infection with a few dormant bacilli. In such cases, the only 
evidence of infection may be a positive tuberculin skin test. In 5% of the cases, the 
bacilli overwhelm the immune response and multiply resulting in a primary TB 
within a few months to a maximum of 5 years (Enarson et al., 2000). Post-primary 
TB occurs when the latent infection is reactivated or when the individual is 
reinfected (van Rie et al., 1999; Sonnenberg et al., 2001; Lillebaek et al., 2002). 
Post-primary TB is characterized by extensive tissue destruction and cavitation, and 
mainly affects the lungs but can also involve the other organs (WHO, 2004).  
 
1.1.3 Tuberculosis Diagnosis 
There are two approaches to TB diagnosis; the first approach is to diagnose 
TB infection, while the second one is to diagnose TB disease. The highest priority 
for TB control is to detect and cure the TB disease especially infectious cases, 
patients with sputum smear positive PTB, because these patients are the main sources 
of TB transmission (WHO, 2003). 
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1.1.3 (a) Diagnosis for Tuberculosis Infection 
Persons with TB infection refer to those who have been exposed to someone 
who has TB disease and have been infected with M. tuberculosis. However, they 
may not feel sick or have symptoms and can not spread the TB to the others. The 
Mantoux tuberculin skin test is the standard method for identifying the TB infection. 
Reaction to a tuberculin skin test is measured 48 to 72 hours after the injection and 
classified as positive when ≥ 5 mm diameter in the absence of previous Bacille 
Calmette-Guerin (BCG) vaccination and ≥ 10 mm diameter in those who have been 
vaccinated with BCG (American Thoracic Society [ATS], 2000; Ayatollahi, 2006).  
The tuberculin skin test is a valuable tool, but it is not perfect. Several factors 
can affect skin test reactions. For example, a false positive test result may present 
when persons have an infection with mycobacteria other than M. tuberculosis or have 
had vaccination with BCG. Conversely, a false negative skin test may occur in 
persons who have anergy, HIV infection, severe malnutrition, recent TB infection, or 
immunosuppressive therapy (ATS, 2000; Centers for Disease Control and Prevention 
[CDC], 2009). In countries where TB is prevalent, the TB skin test is of little value in 
the diagnosis of TB in adults. A positive tuberculin skin test does not by itself 
distinguish M. tuberculosis infection from TB disease (ATS, 2000; CDC, 2005).    
 
1.1.3 (b) Diagnosis for Tuberculosis Disease 
Diagnosis for Pulmonary Tuberculosis. Diagnosis of pulmonary TB can be 
performed by sputum smear microscopy alone or in combination with a sputum 
culture, and chest radiography if resources are available. Direct microscopic 
examination of the sputum is the most cost-effective method of detecting the 
infectious cases in high prevalence countries, because it is inexpensive, rapid, and 
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easy to perform (WHO, 2004; Ozkutuk et al., 2007). Microscopic examination by 
acid fast staining procedures such as Ziehl-Neelsen method is the first step to detect 
acid fast bacilli (AFB). Although sensitivity of direct microscopic examination 
ranges from 22 to 78% when compared to sputum culture as a gold standard, 
obtaining multiple samples can increase the sensitivity of sputum microscopy (Aung 
et al., 2001; Yassin and Cuevas, 2003). Tuberculosis suspects defined as persons 
who cough for more than two weeks should submit three sputum samples for 
microscopy (WHO, 2003b). The chances of finding tubercle bacilli are greater with 
three samples than two or one sample. In most cases, a chest X-ray is unnecessary; 
except for individuals for whom there is clinical suspicion of TB despite negative 
sputum smear (Kisa et al., 2002; WHO, 2003b; WHO, 2004; Ozkutuk et al., 2007). 
In some countries, the initial diagnosis test is a chest X-ray (Jaramillo, 1998). 
However, sputum smear microscopy must always be performed for better diagnosis. 
Although culture is much more sensitive than microscopy, routine sputum culture for 
diagnosis is not feasible and thus, not recommended especially in poor countries 
(Srikanth et al., 2009). Sputum culture results take a long processing time which may 
be too late to monitor the progress of the diagnosis and treatment. 
Diagnosis for Extra-pulmonary Tuberculosis. Definitive diagnosis of extra-
pulmonary TB is often difficult. Diagnosis may be presumptive, provided you can 
exclude other conditions. The diagnosis of individual cases of extra-pulmonary TB is 
a clinical activity. The degree of certainty of diagnosis depends on the clinical 
history, the availability of diagnosis tools such as specialized X-rays or biopsy 
procedures (WHO, 2004). Many patients with extra-pulmonary TB also have co-
existent pulmonary TB, therefore they need sputum examination for AFBs.  
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1.1.4 Disease Classification 
Tuberculosis disease is classified by site of the disease as pulmonary and 
extra-pulmonary TB. Definitions of disease classification are described as follows: 
Pulmonary Tuberculosis. Pulmonary TB refers to disease involving the lung 
parenchyma. A patient with both pulmonary and extra-pulmonary TB should be 
classified as a case of pulmonary TB. There are six categories of pulmonary TB at 
admission to TB care: 1) New, defined as a patient who has never had treatment for 
TB or who has taken anti-TB drugs for less than one month. New patients are sub-
grouped into new smear positive and new smear negative; 2) Relapse, defined as a 
patient previously treated for TB who has been declared cured or treatment 
completed, and is diagnosed with bacteriologically positive (smear or culture) TB 
again; 3) Treatment after failure, defined as a patient who has started on a re-
treatment regimen after having failed previous treatment; 4) Treatment after default, 
defined as a patient who returns to treatment, positive bacteriologically, following 
interruption of treatment for 2 months or more; 5) Transfer in, defined as a patient 
who has been transferred from another TB register to continue treatment; and 6) 
Other, defined as all cases that do not fit the above definitions. This group includes 
chronic case, a patient who is sputum positive at the end of a re-treatment regimen 
(treatment after relapse, treatment after failure and treatment after default), (WHO, 
2003c).  
Extra-pulmonary Tuberculosis. Extra-pulmonary TB refers to TB of organs 
other than the lungs such as pleura, lymph nodes, bones, abdomen, skin, joints, 
genitourinary tract and meninges (WHO, 2003b).  
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1.1.5 Tuberculosis Treatment 
Treatment of TB based on standardized short course chemotherapy regimens 
is the cornerstone of disease control. Standardized regimens have advantages over 
individualized regimens because they reduce errors in prescription, facilitate 
estimates of drug needs and facilitate staff training. There are three main properties 
of anti-tuberculosis drugs: bactericidal activity, sterilizing activity and the ability to 
prevent resistance. Isoniazed (H) and rifampicin (R) have a powerful bactericidal 
effect; in addition to this effect rifampicin is considered the most potent sterilizing 
drug available. Pyrazinamide (Z) and streptomycin(S) are also bactericidal drugs. 
Ethambutol (E) and thiocetazone (T) are bacteriostatic drugs and used to prevent the 
emergence of resistant bacilli (WHO, 2004). According to the World Health 
Organization guideline in tuberculosis treatment (WHO, 2004), the treatment period 
consists of two phases: an initial phase and a continuation phase, and there are four 
categories (CAT) for TB treatment:  
Category I (CAT I). This category is used for tuberculosis patients who are: 
new smear positive patients, new smear negative PTB with severe disease and severe 
forms of extra-pulmonary tuberculosis. The total duration takes at least eight months; 
an initial phase is two months with isoniazed, rifampicin, pyrazinamide and 
ethambutol followed by the continuation phase for six months with isoniazed and 
ethambutol (2RHZE/6HE).  
Category II (CAT II). This category is used for patients with treatment after 
relapse, treatment after failure and treatment after default. The total duration takes at 
least eight months; three months for an initial phase and five months for a 
continuation phase. Treatment for an initial phase consists of: 1) two months with 
isoniazed, rifampicin, pyrazinamide, ethambutol and streptomycin and 2) one month 
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with isoniazed, rifampicin, pyrazinamide and ethambutol. Treatment for the 
continuation phase takes at least five months with isoniazed, rifampicin and 
ethambutol (2RHZES/1RHZE/5RHE).  
Category III (CAT III). This category is used for patients with new smear 
negative pulmonary (other than CAT I) and less severe forms of extra-pulmonary 
tuberculosis. CAT III takes also at least eight months (2RHZ/6HE). It is similar to 
CAT I but ethambutol may be omitted during the initial phase for patient whose a 
chest X-ray shows non-cavitary; smear negative PTB patients who are known to be 
HIV-negative. According to WHO recommendation, recently the use of this 
treatment regimen has been stopped in NTCP of Yemen. The cases under this 
category were included into the category one.  
Category IV (CAT IV). This category is used for patients with chronic and 
multidrug resistant tuberculosis (MDR-TB) cases, defined as patients with resistance 
to at least both isoniazid and rifampicin. This category uses individualized regimens 
depending on the drug sensitivity test.  
At the end of the treatment course, each patient is evaluated and assigned into 
one of the six categories of treatment results: 1) cured, defined as a patient who is 
sputum smear negative in the last month of treatment and on at least one previous 
occasion; 2) completed, defined as a patient who has completed treatment but who 
does not meet the criteria to be classified as a cure or a failure; 3) failed, defined as a 
patient who is sputum smear positive at five months or later during treatment; 4) 
died, defined as a patient who dies for any reason during the course of treatment; 5) 
defaulted, defined as a patient whose treatment was interrupted for two consecutive 
months or more; and 6) transferred out, defined as a patient who has been transferred 
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to another recording and reporting unit and for whom the treatment outcome is not 
known (WHO, 2003c). 
 
1.1.6 Disease Control 
The most cost-effective public health measure for the control of tuberculosis 
is to detect and cure infectious tuberculosis patients, defined as patients with smear 
positive PTB (WHO, 2003b). However, tuberculosis control programmes also 
provide the same care for other types of TB patients as well. 
Tuberculosis has been recognized as a global emergency because of the 
increasing number of patients worldwide. Tuberculosis as an emergency was 
declared by WHO since 1993 (WHO, 1998; Gandy and Zumla, 2002). To face this 
emergency, the WHO has developed a new policy and strategy. The current global 
strategy for effective control is the direct observed therapy short course (DOTS). It 
has five key components. First, is the government commitment to sustain TB control 
activities. Second, is the case detection by sputum smear microscopy among 
symptomatic patients. Third, is the standardized treatment regimen of at least six to 
eight months for confirmed sputum smear positive cases, with direct observed 
therapy (DOT) for at least the initial two months. DOT means that an observer 
watches the patient swallowing their tablets in a way that is sensitive and supportive 
to the patients' needs. This ensures that a tuberculosis patient takes the right anti-
tuberculosis drugs in the right doses at the right intervals. In theory, the observer may 
be a health worker or a trained community member. However, in practice, the 
observers are usually family members of the patients. Fourth, is a regular, 
uninterrupted supply of all essential anti-tuberculosis drugs. Fifth, is a standardized 
recording and reporting system that allows assessment of treatment results for each 
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patient and overall of the tuberculosis control programme (WHO, 2003a). The DOTS 
strategy has been implemented worldwide with a wide variation in success of the 
programme.  
 
1.2 Tuberculosis Situation in Yemen 
Yemen is one of the intermediate TB burdened countries in the Eastern 
Mediterranean Region. Tuberculosis is one of the major public health problems in 
Yemen ranking 4th in the list of priority public health problems (NTCP, 2010). 
 
1.2.1 Demographic and Epidemiological Data 
Yemen is an Arabian country located in the south west of Arabian Peninsula 
with 24 million population.  It is located in an area of 555000 km2. Yemen is divided 
into 21 governorates which subsequently divided into 333 districts. Table 1.1 shows 
the demographic and the epidemiologic data of Yemen. 
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Table 1.1: Demographic and Epidemiological Data (2011) 
Demographic data  
Birth rate (per/1000 population) 32.6 
Death rate (per/1000 population) 6.8 
Infant mortality rate (per1000 live birth) 53.5 
Life expectancy at birth male 62.1 
Life expectancy at birth female 66.3 
Economy  
GNI per capita US$ 2300 
Education 
Rate of primary school enrolment 72.6% 
Rate of illiteracy  36.1% 
Proportion of population in broad age group  
Age 0-14 15-64 65+ 
% 43.0 54.4 2.6 
BCG coverage 
Year 2006 2007 2008 2009 2010 2011 
Coverage 67% 64% 60% 58% 65% 59% 
Epidemiology of TB 2009 
Total population                         24 million   
Annual Incidence of PTB smear positive  6,000      (25/100000 population) 
Total Incidence of all forms of TB 14,400    (60/100000 population) 
Prevalence 18,720    (78/100000 population) 
Mortality (2000-2500) person (9.4/100000 population) 
Source: https://www.cia.gov/library/publications/the-world-factbook/geos/ym.html 
 
Based on hospitals statistics it is estimated that TB is the 4 PthP cause of death in 
Yemen. As shown in the previous table, there are about 2000-2500 TB cases of all 
forms that die from TB annually with mortality rate of 9.4 per 100000 population. 
According to the Yemen NTCP guideline, the latest estimated incidence of all 
forms of new TB cases was 14400 with a rate of 60 per 100000 population. The 
estimated incidence rate of new smear positive PTB was 25 per 100000 population 
with an estimated 6000 new smear positive cases in 2009. 
During 2009, a total of 3576 new smear positive PTB cases were reported to 
NTCP with notification rate of 15 per 100000 population. The case detection rate 
(CDR) was 60%. All forms of notified TB cases were 8248 TB cases. The CDR was 
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57%. The estimated prevalence of all forms of TB cases is 78 per 100000 population 
with 18720 estimated prevalent cases. There were 1900 TB deaths in 2009, with a 
mortality rate of 7.9 per 100000. Seventy three percent (73%) of all notified new 
pulmonary smear positive cases are in the most productive age groups (15-49 years 
old). The male/female ratio reached up to 1.3 in 2009 (NTCP, 2010).  
DOTS coverage reached 100% within Ministry of Health facilities in 2007. 
Treatment success rate increased from 50% before DOTS implementation to 84% for 
2008. 
Tuberculosis case notification declined steadily from 2000. However, the 
question of whether this decrease was true epidemiologically or related to operational 
factors is still unsolved. However, the last survey conducted in 2009, showed that the 
incidence of new smear positive PTB was 25 per 100000 population (NTCP, 2010).  
Tuberculosis case detection among children was always below 2 per 100000 
population indicating that TB among the children was under detected. This is 
because children at younger ages can not produce sputum and diagnosis by primary 
health care remains difficult (NTCP, 2010). 
According to the multidrug resistant survey done by the Research Institute of 
Tuberculosis (RIT) Japan during the year 2004-2005, MDR was found to be 2.9% 
among new smear positive cases and 11.3% among previously treated cases.  
Based on a recent survey completed on TB-HIV co-infection in collaboration 
with the HIV-AIDS programme, it has been observed that among 900 TB cases there 
were 6 HIV positive cases which was below < 1% (NTCP, 2010; WHO, 2010). 
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1.2.2 History Development and Organization of NTCP  
Tuberculosis control programmes were launched in 1970s in previous two 
parts of Yemen (North and South). After the unification on the 22nd May 1990, the 
Ministry of Public Health and Population (MoPH&P) established the directorate of 
NTCP within the General Directorate of Public Health. 
In 1983, the cooperation between Yemen and Japan International Cooperative 
Agency (JICA) was started. The WHO and the JICA are the only Donor Agencies for 
Yemen NTCP. In 2001, MoPH&P assigned a running budget for NTCP compared of 
sponsoring only the NTCP staff salaries in the past.  Along with MoPH&P and 
WHO, the Global Facility (GF) also contributed supporting the NTCP in 2004. 
NTCP is a tool for TB control strategy implementation within a national 
health system. As such, the NTCP is a vehicle for the DOTS strategy. NTCP 
policies, plans and activities are designed to achieve efficient case finding and 
treatment of TB patients. The NTCP should be countrywide, continuous, permanent 
and integrated into the existing national health services. For patients, the NTCP aims 
to cure the disease, quickly restore their capacity for daily life activities and allow 
them to remain within their family and community (NTCP, 2010). For the 
community, the purpose of the NTCP is to stop the spread of TB infection and 
prevent a costly public health crisis. 
 
1.2.3 NTCP Organizational Framework 
The Ministry of Public Health and Population established a National 
Tuberculosis Control Programme in 1995. It is a detailed plan of action for effective 
TB control. There must be four levels of responsibility to ensure efficacy of TB 
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control: peripheral, district, governorate and central levels. Each of these levels is 
well defined with different tasks (NTCP, 2010). 
Peripheral level. The NTCP is implemented through the network of health 
centers and health units at the peripheral level and the role of these facilities is to 
offer basic TB services to the patients such as DOT, health education, defaulters 
tracing, identifying TB suspects and refer them to TB diagnostic centres. A medical 
officer or medical assistant in-charge of the peripheral health facilities is responsible 
for the implementation. 
District level. It is the basic unit of management for DOTS implementation 
serving a population of 30000-150000. The Director General and Primary Health 
Care Director of Governorate Health Office designate, in consultation with 
Governorate TB Coordinator (GTC), a District TB Coordinator (DTC), who is 
responsible of all TB control activities within the district (diagnosis, treatment, 
follow up, training, supervision, logistics, etc.).  
Governorate level. The Director General of Health Office gives guidance and 
support to the Primary Health Care Director in implementing the NTCP policies 
throughout the network of Primary Health Care (PHC)  in the Governorate. The 
Director General of Health Office appoints a GTC who is responsible of planning 
and supervision all TB control activities within the Governorate. The Director 
General of Health Office also appoints the Governorate Laboratory Supervisor 
(GLS) who is responsible for quality control of TB laboratories in the Governorate. 
Central level. The primary responsibility is to ensure that TB control is 
implemented effectively and uniformly throughout the country. The Directorate of 
Tuberculosis Control in MoPH&P is the central unit of National Tuberculosis 
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Control Programme under guidance and instructions of Director General of Diseases 
Control and Surveillance and Under-Secretary of Primary Health Care. 
 
1.2.4 Relapse of Tuberculosis in Yemen 
Relapse of tuberculosis is defined as the circumstance in which a patient 
previously treated for TB who has been declared cured or treatment completed, and 
is diagnosed with bacteriologically positive (smear or culture) TB (WHO, 2003a).  
Relapse of tuberculosis is a serious problem that could hamper TB control 
and the success of the National Tuberculosis Control Programme in Yemen. The 
relative relapse rate is high among all years exceeding the acceptable norm (< 5%) 
(Caminero et al., 1996; WHO, 1997; Connolly et al., 1999; Vernon, et al., 1999; 
Chang et al., 2006). Table 1.2 shows the number of new positive TB cases and 
relapse cases as well as the relative relapse rate during the past years (1995-2009). 
 
 
   Table 1.2: New Smear Positive and Relapse Cases during 1995-2009 
Year New Smear Positive Cases Relapsed Cases Relative Relapse Rate (%) 
1995 3681 375                       9 
1996 4371 298 6 
1997 4717 344 7 
1998 4896 297 6 
1999 5427 475 8 
2000 5565 440 7 
2001 4968 584 11 
2002 4259 436 9 
2003 3793 426 10 
2004 3434 377 10 
2005 3379 351 9 
2006 3337 311 9 
2007 3537 325 8 
2008 3540 411 10 
2009 3576 314 8 
Average 4165 384 8.4 
  Source: NTCP Report 2010 
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Referring to the Table 1.2, it was noticed that after simultaneous decline of 
TB till 2006, new cases were seen to increase again from 2007. Regardless of this 
negative point of TB control in Yemen, the country is still among the moderate TB 
prevalence countries in the world. Hence, the resurgence of tuberculosis is not a case, 
as far as the threat of relapse, especially if such increase can be justified. The relapse 
of tuberculosis is an important issue and has to be taken into consideration. The 
relapse rate exceeded the acceptable norm (i.e., < 5%) and could seriously affect the 
success of DOTS strategy applied in the country.  
Understanding the phenomenon of the relapse of tuberculosis is important to 
identify the factors that actually contribute to the phenomenon. Hence, a list of 
factors were explored which include:- demographic, socioeconomic, co-morbidity, 
treatment and disease-related factors as well as patients' compliance and the factors 
evaluated after 2-3 months of treatment (i.e., presence of positive smear at the end of 
the second or the third month and gaining weight at the end of the second month).  
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 1.3 Patients’ Compliance to Anti-Tuberculosis Treatment  
Compliance means following a rule or procedure as directed. For example, 
for a TB patient compliance means taking anti-TB drugs as scheduled (WHO, 
2003a).  
Non-compliance with the treatment of tuberculosis is a major problem that 
leads to treatment failure, relapses and emergence of drug resistance (Comolet et al., 
1998; Al-Hajjaj and Al-Khatim, 2000; Pandit and Choudhary, 2006; Bagchi et al., 
2010; Vijay et al., 2010). Non-compliance places the patients at risk for the 
individual health, their family and the wider community, as well as wasting health 
resources (McLean, 2003). 
The public health priority of a National Tuberculosis Control Programme is 
the cure of smear positive tuberculosis cases, while preventing the emergence of drug 
resistance. Patients’ compliance as a key factor in treatment success should be 
ensured to achieve this priority (WHO, 2003).  
Many studies have consistently found that non-compliance to anti-TB 
treatment was associated with relapse of tuberculosis (Selassie and Wilson, 2002; 
Thomas et al., 2005; Selassie et al., 2005; Picon et al., 2007). According to NTCP 
annual report of 2006, a default rate was high (0-20%) in all Yemeni governorates 
exceeding the WHO norm (10%). 
Compliance is a critical factor in successful TB control; hence it becomes a 
priority in this study. The patients’ compliance was studied as an independent 
variable of relapse and a dependent. A list of the independent variables expected to 
affect the patients’ compliance were explored. The factors studied on compliance 
were demographic, socioeconomic and knowledge on TB and its treatment as well as 
education at the health centre and presence of adverse reactions.  
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1.4 Economic Impact of Tuberculosis  
Tuberculosis is the first killer disease that kills nearly two million people 
every year at their most economically productive age (15-54 years old). On average, 
a TB patient loses three to four months of work time due to illness, equivalent to 20-
30% of annual household income and about 15 years of income lost due to premature 
death (WHO, 2003). In addition to the devastating economic costs, TB imposes 
indirect negative consequences among women with TB who are unable to practice 
their essential responsibilities for their families; the person with TB can be rejected 
from community, friends and even family. Increasing loss of income in seeking 
health care for TB makes the households changing their strategies to reduce total 
family expenses. Thus, the children could miss their education opportunities, food 
intake could decrease and the family might need to sell some of their assets and 
borrowing money from others (WHO, 2000; Elamin et al., 2008).  
 
1.5 Problem Statement 
Yemen as in many developing countries is trying to eliminate this killer 
disease.  According to WHO global tuberculosis database 2007 and some data from 
the statistics department in National Tuberculosis Control Programme, Yemen is 
close to WHO target of treatment success rate (85%). Despite of this high success 
rate, the relapse of tuberculosis remains a problem in TB control of Yemen where the 
relative relapse rate ranged between 6 to 11% during all previous years i.e., from 
1995 to 2009 (Table 1.2).   
Based on 2006 report by NTCP, it is estimated that the relative relapse rate 
was between 3% to 20% in all governorates as a whole and between 0% to 29% 
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among urban areas (Table 1.3). The high rate of relapse could be the leading cause 
for transmission of resistant M. tuberculosis. 
 
Table 1.3: Relative Relapse Rate in Yemen (2006) 
R
eg
io
n 2006 Overall Country Urban Areas 
Governorate NSm+ Relapsed RR (%) NSm+ Relapsed RR (%) 
So
ut
h 
Abyan 162 12 7 98 3 3 
Aden 239 46 16 239 41 14 
Lahj 149 6 4 96 2 2 
Taiz 478 40 8 308 34 10 
M
id
dl
e 
Al-Baidah 57 14 20 47 2 4 
Al-dhale 69 5 7 52 4 7 
Dhamar 208 14 6 71 7 9 
Ibb 142 13 8 113 9 7 
W
es
t 
Al-Hodeidah 689 57 8 194 26 12 
Al-Mahweit 62 2 3 8 0 0 
Hajjah 256 35 12 27 11 29 
Raimah 36 1 3 13 0 0 
N
or
th
 
Al-Jawf 46 5 10 7 0 0 
Amran 63 6 9 18 2 10 
Metropolitan  315 25 7 66 8 11 
Saddah 62 2 3 16 0 0 
Sana'a  75 3 4 16 0 0 
Ea
st
 
Al-Mahara 17 1 6 15 1 6 
Hadramout 120 19 14 69 7 9 
Mareb 57 3 5 28 3 10 
Shabwah 35 2 5 16 0 0 
  Total 3337 311 8.5 1517 160 9.5 
NSm+ =New Smear Positive Cases; RR= Relative Relapse Rate; Source: NTCP Report 2006 
 
Relapse of tuberculosis results in a great negative impact on tuberculosis care 
for patients, the TB control programme and the local community. For the patient, 
relapse of tuberculosis can lead to lose patients’ trust on the NTCP, the use of more 
complex and longer treatment regimen, increased possibilities of unsuccessful 
treatment outcomes, higher chances to develop drug resistance, and higher risks of 
morbidity and mortality are main concerns (WHO, 2006). For the TB control 
programme, the defaulters of relapsed cases remain infectious and could be the 
leading cause for transmission of resistant M. tuberculosis to the other people in the 
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community (WHO, 2006). In addition, larger amounts of resources (e.g., financial 
and human resources) needed to be allocated to treat recurrent patients. If there is 
high number of relapsed cases, it will be difficult for any programme to control the 
tuberculosis. Therefore, relapse has serious implications on both individuals and 
communities.  
 
1.6 Rational and Importance of the Study 
Yemen is one of the developing countries where tuberculosis is a major 
concern. Tuberculosis costs the country wasting a lot of resources and relapse of TB 
complicates this situation. To study the factors which may be associated with relapse 
is a promising tool to reduce the incidence of TB relapse and preventing resurgence 
of MDR tuberculosis. Once the relapse incidence is reduced the resources consumed 
to control TB will be reduced. Hence, there will be less burden economically on the 
government, society or individual. Money saved can be then used for TB control.  
Relapse of TB is defined as the circumstance in which a patient previously 
treated for TB who has been declared cured or treatment completed, and is diagnosed 
with bacteriologically positive (smear or culture) TB (WHO, 2003a). A recurrent 
episode can be caused by either endogenous relapse (reactivation) of the same strain 
of the initial episode, following insufficient bacterial cure, or exogenous new 
infection of a strain of M. tuberculosis (reinfection). TB recurrence has been reported 
to occur within an acceptable rate (< 5%) after a wide application of effective anti-
TB drugs in combination for at least 6 months in a largely HIV-negative environment 
(Weis et al., 1994; Chan et al., 1994). However, recent reports and studies showed 
that there was a noticeably increasing trend in TB recurrence globally (Connolly et 
al., 1999; Sonnenberg et al., 2001; Panjabi et al., 2007; Glynn et al., 2010; 
Nyamogoba et al., 2012). In 2009, more than 270,000 recurrent cases were reported 
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worldwide (WHO, 2010). Evidence from recent studies suggests that the TB 
recurrence rate has surpassed that of TB incidence (Connolly et al., 1999; Verver et 
al., 2005). Being an important index to assess the long-term effectiveness of TB 
control programme, the increased recurrence rates have raised significant concerns 
among researchers and public health practitioners on the current TB control strategy, 
i.e., “Directly Observed Therapy, Short-course”. Moreover, heavy burdens imposed 
by elevated recurrence risk on both individual patients and TB Control Programmes 
call for intensive investigations and practical interventional strategies to control this 
trend. 
Relapse of tuberculosis is a serious problem that could hamper TB control and 
success of National Tuberculosis Control Programme in Yemen and found to be 
higher than the acceptable norm (< 5%). Through the investigation of TB relapse 
rates and its associated risk factors, the burden from TB relapse would be quantified 
and important messages regarding the control of TB relapse will be conveyed to both 
National TB Control Programme and other programmes under similar settings. 
 During the last 5 years a high cure rate (85%) was achieved in Yemeni DOTS 
programme. In contrast, the unduly relative relapse rate (3% to 20%) has been seen. 
It is generally accepted that if DOTS is widely practiced to a high standard and with 
a high cure rate, the tuberculosis epidemic should subside. High cure rates with 
rifampicin-based chemotherapy throughout the treatment should also be associated 
with a low relapse rate (< 5%). Some reports suggested that in a routine setting 
relapse rates can be considerably higher, for various reasons such as use of 
ethambutol in the continuation phase instead of rifampicin or a high TB transmission 
pressure in the community (Chan et al., 1994). If this is true, then even after having 
achieved the global goal of 70% case detection rate and 85% cure rate, the 
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elimination of the TB problem will not be guaranteed. Therefore, it is necessary to 
address the possibility of unduly high relapse rates in Yemen under apparently high 
cure rates in routine programme conditions. 
  
1.7 Main Aims of the Study 
The general aims of this study are to reduce relapse rate of tuberculosis, 
enhancing patients' compliance and to determine the economic burden of 
tuberculosis relapse in Yemen. To achieve these aims, the following specific 
objectives were investigated: 
1. To study, under DOTS programme conditions, the effect of different 
factors on TB relapse in NTCP of Yemen. 
2. To study the effect of different factors on patients’ compliance.  
3. To evaluate direct cost of TB relapse from government perspective. 
 
1.8 Significance of the Study Findings 
The effect of compliance and factors behind it as well as other possible 
causes for the tuberculosis relapse and its subsequent cost has not been studied in 
Yemen. The findings of the present study should elucidate the factors that affect 
relapse of tuberculosis and patients’ compliance as well as its consequential 
economic burden. It should also provide both the community and the government 
with information on what should be done to ensure compliance to anti-TB treatment.  
By identifying factors associated with the relapse and non-compliance, the 
incidence of the relapse and non-compliance could be decreased thus lead to 
reduction in patient and society expenditure as well as depletion of limited 
government resources. In addition, such findings will positively contribute in 
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achieving the general aims i.e., reducing of tuberculosis relapse rate and enhancing 
patients' compliance. Through quantifying the cost of tuberculosis relapse, a 
reduction on the economic burden of tuberculosis in the country could be achieved.  
Through providing evidence on possible cost savings by relapse prevention, the 
findings will provide policy makers and planners with strong argument to justify 
continued allocation of resources for the TB programme. Furthermore, the findings 
could provide baseline information for further monitoring of tuberculosis relapse and 
patients’ compliance in Yemen.  
 
1.9 Summary of the Next Chapters 
The following chapters are literature review, methodology, results, discussion 
and conclusions. The first part of chapter on literature review will provide an 
overview on relapse of tuberculosis and its related factors. The second part on 
literature review will present an overview on treatment compliance and its related 
factors while the third part will deal with a literature review on cost of tuberculosis 
relapse from the government perspective. In this context, the chapter will explore: 1) 
economic impact of tuberculosis; 2) application of pharmacoeconomic in TB 
management; and 3) overview on the literature of tuberculosis cost.   
The methodology chapter will provide a description of the study design and 
brief discussion of human subject protection (confidentiality and ethical issues). 
Thereafter, the study area, study population, inclusion and exclusion criteria and 
sample size calculation will be presented. The procedures for data collection and 
description of the instruments will also be described, followed by a depiction of study 
variables on relapse and compliance. The chapter will end with exploring the 
procedures used to estimate the cost of relapse and data management and analysis. 
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The results chapter reports the results according to the descriptive and inferential 
statistics that were performed in this study.  
Finally, the discussion chapter will provide a discussion on the study findings 
compared to the existing research literature and also implications of the findings. The 
last chapter on conclusions will summarize the main study findings, strengths and 
limitations. The chapter ends with recommendations and suggestions for future 
studies.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
